Actively Recruiting
Phase II Trial of Surgery After Chemotherapy with NALIRIFOX for Pancreatic Cancer with Limited Liver or Lung Metastases
Led by The University of Texas Health Science Center at San Antonio · Updated on 2026-04-14
40
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a surgical treatment for patients with pancreatic cancer that has spread to a limited number of spots in the liver or lungs. This trial evaluates the surgery following pre-operative chemotherapy with a regimen called NALIRIFOX. Patients must have stable or shrinking tumors after initial chemotherapy to be considered for surgery, and those with worsening cancer during treatment are removed from the study. Participants receive four cycles of NALIRIFOX chemotherapy first. After these cycles, if the cancer is stable or responding and the main tumor can be surgically removed, patients will have surgery 2 to 6 weeks later. The surgery aims to remove both the main pancreatic tumor and small metastatic tumors in the liver or lungs. If the tumor is found unresectable during surgery, additional chemotherapy may be given 2 to 4 weeks afterward. During the study, patients are monitored through imaging scans and evaluations by a tumor board to assess tumor status and surgical eligibility. The main outcome measured is the success of surgery in removing all visible cancer classified as R0 or R1 resection within 4 to 12 weeks after surgery. Researchers will also assess safety, quality of life, progression-free survival, recurrence-free survival, and overall survival for up to 25 months after surgery. The study involves regular assessments before and after surgery to track these outcomes.
CONDITIONS
Brief Title
Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
Research Team
L
Lei Zheng, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here